Pr
Principia (Sanofi)
S San Francisco CAFounded 2008100 employees
Private CapbiotechAcquiredImmunology
Platform: BTK MS
Market Cap
N/A
All Drugs
4
Clinical Trials
9
Failed / Terminated
2
FDA Approved
0
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Talafotisoran | PRI-8249 | Phase 1 | 1 | USP1 | Melanoma | ||
| PRI-9923 | PRI-9923 | Phase 2/3 | 2 | BCMA | Gastric CaCKD | ||
| Doxazasiran | PRI-4571 | Preclinical | 2 | KRASG12D | RB | ||
| Semalemzoparlimab | PRI-3145 | Phase 3 | 4 | EGFR | Huntington's |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (9)